Printer Friendly

University of Maryland obtains United States patent.

University of Maryland, Baltimore (Baltimore, MD) has patented a composition comprising a novel Ca.sup.2+-activated, [ATP].sub.i-sensitive nonspecific cation (NC.sub.Ca-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca].sub.i. The NC.sub.Ca-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NC.sub.Ca-ATP channel is regulated by a sulfonylurea receptor and is inhibited by sulfonylurea compounds glibenclamide and tolbutamide. Methods employing compositions comprising the NC.sub.Ca-ATP channel to screen for compounds that block the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. In addition, methods employing compositions comprising the Kir2.3 channel to screen for compounds that open the channel and the use of such antagonists as therapeutics in preventing brain swelling and damage are described. (US 7,285,574)
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief article
Geographic Code:1USA
Date:Oct 1, 2007
Words:167
Previous Article:Katholieke Universiteit Nijmegen obtains United States patent.
Next Article:Massachusetts Institute of Technology obtains United States patent.
Topics:


Related Articles
Utah State University obtains United States patent.
Genentech antibody patent issues - licensed to MedImmune.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |